122 related articles for article (PubMed ID: 9157949)
1. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance.
de Villiers WJ; van der Westhuyzen DR; Coetzee GA; Henderson HE; Marais AD
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):865-72. PubMed ID: 9157949
[TBL] [Abstract][Full Text] [Related]
2. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
[TBL] [Abstract][Full Text] [Related]
4. Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia.
Lohse P; Rader DJ; Brewer HB
J Biol Chem; 1992 Jul; 267(19):13642-6. PubMed ID: 1352296
[TBL] [Abstract][Full Text] [Related]
5. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
[TBL] [Abstract][Full Text] [Related]
6. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus.
Eto M; Watanabe K; Sato T; Makino I
J Clin Endocrinol Metab; 1989 Dec; 69(6):1207-12. PubMed ID: 2584356
[TBL] [Abstract][Full Text] [Related]
8. Severe hyperlipidemia in apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism.
Sijbrands EJ; Hoffer MJ; Meinders AE; Havekes LM; Frants RR; Smelt AH; De Knijff P
Arterioscler Thromb Vasc Biol; 1999 Nov; 19(11):2722-9. PubMed ID: 10559017
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
10. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Nissen H; Hansen TS
Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
[TBL] [Abstract][Full Text] [Related]
11. A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Gröne HJ; Lohmer S; Wohlfeil S
Am J Hum Genet; 1996 Feb; 58(2):281-91. PubMed ID: 8571954
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
[TBL] [Abstract][Full Text] [Related]
13. Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
Sinnott BP; Mazzone T
Endocr Pract; 2006; 12(2):183-7. PubMed ID: 16690468
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of type III hyperlipoproteinemia in Germany.
Feussner G; Feussner V; Hoffmann MM; Lohrmann J; Wieland H; März W
Hum Mutat; 1998; 11(6):417-23. PubMed ID: 9603433
[TBL] [Abstract][Full Text] [Related]
15. [Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patient].
Ziemer A; Göring HD
Hautarzt; 1993 Aug; 44(8):538-44. PubMed ID: 8376110
[TBL] [Abstract][Full Text] [Related]
16. Dysbetalipoproteinaemia--clinical and pathophysiological features.
Blom DJ; Byrnes P; Jones S; Marais AD
S Afr Med J; 2002 Nov; 92(11):892-7. PubMed ID: 12506591
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.
Evans D; Seedorf U; Beil FU
Clin Genet; 2005 Oct; 68(4):369-72. PubMed ID: 16143024
[TBL] [Abstract][Full Text] [Related]
18. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
19. Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping.
Walden CC; Huff MW; Leiter LA; Connelly PW; Hegele RA
J Clin Endocrinol Metab; 1994 Mar; 78(3):699-704. PubMed ID: 7907341
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
